RECURSION PHARMACEUT

Item 7.01 Regulation FD Disclosure.

On January 10, 2022, Recursion Pharmaceuticals, Inc. released an updated
investor presentation. The investor presentation will be used at the JP Morgan
Healthcare meeting and from time to time in meetings with investors. A copy of
the presentation is attached hereto as Exhibit 99.1.

The information furnished pursuant to Item 7.01 on this Form 8-K, including
Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference into any other filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as expressly set forth by
specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



Exhibit No. Description

99.1 Investor presentation of Recursion Pharmaceuticals, Inc. dated
January 10, 2022.

104 Cover Page Interactive Data File (formatted as Inline XBRL)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses